[(225)Ac]Ac- and [(111)In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts

BACKGROUND: Trastuzumab (Herceptin) has improved the outcome for patients with HER2-positive breast cancer (BC) but brain metastases (BM) remain a challenge due to poor uptake of trastuzumab into the brain. Radioimmunotherapy (RIT) with trastuzumab labeled with α-particle emitting, (225)Ac may overc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kondo, Misaki, Cai, Zhongli, Chan, Conrad, Forkan, Nubaira, Reilly, Raymond M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522541/
https://www.ncbi.nlm.nih.gov/pubmed/37750937
http://dx.doi.org/10.1186/s41181-023-00208-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522541/
https://www.ncbi.nlm.nih.gov/pubmed/37750937
http://dx.doi.org/10.1186/s41181-023-00208-0

Ejemplares similares